Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets

• Tipo: Artigo em Revista Científica Internacional
• Data: 2021

Autores

Marta R Couto (Autor) FMUP; Pereira Terra, P (Autor) Outra; Quelhas Santos, J (Autor) FMUP; Silva Pereira, C (Autor) Outra; Albino Teixeira, A (Autor) Outra; Sousa, T (Autor) FMUP

Revista

Título: Frontiers in Physiology

Vol. 12

ISSN: 1664-042X

Editora: Frontiers Media

Indexação

ISI Web of Knowledge - 81 Citações

Scopus - 89 Citações

Outras Informações

ID Authenticus: P-00V-H7Z

DOI: 10.3389/fphys.2021.746494

Abstract (EN): Inflammation has been recognized as a major pathophysiological contributor to the entire spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with preserved ejection fraction, acute HF and cardiogenic shock. Nevertheless, the results of several trials attempting anti-inflammatory strategies in HF patients have not been consistent or motivating and the clinical implementation of anti-inflammatory treatments for HF still requires larger and longer trials, as well as novel and/or more specific drugs. The present work reviews the different inflammatory mechanisms contributing to each type of HF, the major inflammatory mediators involved, namely tumor necrosis factor alpha, the interleukins 1, 6, 8, 10, 18, and 33, C-reactive protein and the enzymes myeloperoxidase and inducible nitric oxide synthase, and their effects on heart function. Furthermore, several trials targeting these mediators or involving other anti-inflammatory treatments in human HF are also described and analyzed. Future therapeutic advances will likely involve tailored anti-inflammatory treatments according to the patient's inflammatory profile, as well as the development of resolution pharmacology aimed at stimulating resolution of inflammation pathways in HF.</p>

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 25